AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled "Thought Leader Insight & Analysis: Alzheimer's Disease," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area (http://www.medpredict.com/website/home.aspx) (see also Alzheimer Disease).
MedPredict interviewed renowned Alzheimer's disease thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs. Interviews for this report were conducted following the 2009 American Academy of Neurology (AAN) conference.
"In this report, our panel of experts describes the clinical progress of the most interesting therapeutic and diagnostic candidates in the pipeline," according to Jeff Berk, MedPredict's president and lead author of this report. "The panel covers active and passive immunologic approaches that hold promise in prevention of Alzheimer's disease and treatment at the earliest stages of dementia."
"The panelists rank the most promising small molecules and antibodies that are targeting amyloid and plaques, offering their opinions on gamma-secretase inhibitors and modulators, beta-secretase inhibitors, Tau phosphorylation inhibitors, cardiovascular agents, anti-amyloids and aggregation inhibitors, histone deacetylases (HDACs), SIRT-1, metal chelators and ...
Source: HighBeam Research, New MedPredict Report Reveals Top Alzheimer's Experts' Insights on...